Creating Better Tomorrows
We are medical pioneers.
We uncover new therapies, test unique molecules, and discover innovative medicines that create better tomorrows for all women. We are . . . Curatek Pharmaceuticals.
Curatek Pharmaceuticals is a privately held pharmaceutical company focused on discovering new therapies for specific, difficult-to-diagnose conditions in women. With more than 40 years of combined experience in pharmaceutical research and development, the founders of Curatek have developed a portfolio of best-in-class products primarily focused on women’s health. For example, the company has successfully developed and commercialized the products MetroGel® Topical Gel* for rosacea (divested to Galderma) and MetroGel®-Vaginal* for bacterial vaginosis (divested to 3M Pharmaceuticals).
*MetroGel and MetroGel-Vaginal are registered trademarks owned by Nestlé Skin Health S.A.
Vaginal infections are some of the most common diseases affecting women globally. They are often difficult to diagnose because there are multiple causes. Curatek Pharmaceuticals is developing innovative therapies to treat two of the most common types of vaginal infections: vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV).
Despite the significant number of women with vaginal infections globally, there have been few advancements in the treatment of these diseases for more than 25 years. There is a clear need for better treatment options. Curatek plans to answer that need with three new product offerings, one of which will be the first product to market in the US with an indication for the treatment of mixed (concomitant) BV and VVC infections.
All three products in development are protected by U.S. patents expiring in 2028, 2030, and 2031. Phase 3 clinical trials have been recently completed and NDAs will soon be ready to file. Currently, these products have not been approved for marketing by the US Food and Drug Administration or other regulatory agency.
These three new products were also granted Qualified Infectious Disease Product (QIDP) designation by FDA. The QIDP designation provides incentives for the development of new drugs to treat serious infections. These incentives include a 5-year extension of market exclusivity, priority FDA review, and fast track status.
Curatek Pharmaceuticals is a privately held company. We focus on discovering new therapies for conditions that are difficult to diagnose or treat, creating better tomorrows for all women. We are pursuing partnerships with companies focused on similar values and missions. If you’re interested in collaborating, reach us at: